CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Shares withheld for taxes President & Immunovant CEO gave up 7,051 shares (to pay taxes)
- 4 Open-market sale Director sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale Director sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale Director by Deputization sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale 10% owner sold 1,854,603 shares at an average $20.46 ($37,939,112)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $20.22 ($4,044,000)
- 4 Grant or award Director acquired 1,056 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 158 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 281 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 851,383 shares at an average $16.99 ($14,467,502)
- 4 Planned sale President & Immunovant CEO sold 125,667 shares at an average $16.29 ($2,047,336)
- 4 Planned sale President & Immunovant CEO sold 665,159 shares at an average $16.21 ($10,781,813)
- 4 Shares withheld for taxes CFO gave up 2,341 shares (to pay taxes)
- 4 Shares withheld for taxes CFO gave up 2,129 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 1,711,000 shares at an average $14.92 ($25,524,777)
- 4 Open-market buy CEO bought 3,315 shares at $15.07 ($49,957)
- 4 Grant or award Director acquired 14,524 shares (grant or award)
- 4 Other disposition Director disposed of 5,270 shares (other)
- 4 Other disposition Director disposed of 937 shares (other)
- 4 Other disposition Director disposed of 2,043 shares (other)
Page 6 of 26 · 511 filings